Zacks Investment Research Lowers GW Pharmaceuticals PLC (NASDAQ:GWPH) to Hold

GW Pharmaceuticals PLC (NASDAQ:GWPH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Monday, July 24th.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

Several other research analysts have also weighed in on GWPH. Maxim Group set a $135.00 target price on shares of GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Thursday, June 8th. BidaskClub upgraded shares of GW Pharmaceuticals PLC from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 14th. TheStreet lowered shares of GW Pharmaceuticals PLC from a “c-” rating to a “d+” rating in a research report on Wednesday, May 10th. ValuEngine upgraded shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $208.00 price target on shares of GW Pharmaceuticals PLC in a research report on Tuesday, May 9th. Five equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $148.55.

GW Pharmaceuticals PLC (NASDAQ:GWPH) opened at 99.92 on Monday. GW Pharmaceuticals PLC has a 52 week low of $79.62 and a 52 week high of $137.88. The stock’s market capitalization is $2.53 billion. The company has a 50-day moving average of $107.69 and a 200-day moving average of $112.86.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the consensus estimate of ($1.73) by $0.34. GW Pharmaceuticals PLC had a negative return on equity of 28.80% and a negative net margin of 1,384.41%. The company had revenue of $3.14 million for the quarter, compared to analyst estimates of $2.10 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share. Analysts anticipate that GW Pharmaceuticals PLC will post ($6.21) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Zacks Investment Research Lowers GW Pharmaceuticals PLC (NASDAQ:GWPH) to Hold” was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/08/19/gw-pharmaceuticals-plc-nasdaqgwph-downgraded-to-hold-at-zacks-investment-research-updated-updated-updated.html.

A number of institutional investors have recently bought and sold shares of the company. IHT Wealth Management LLC increased its position in GW Pharmaceuticals PLC by 18.0% in the second quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 100 shares in the last quarter. Advisor Group Inc. increased its position in GW Pharmaceuticals PLC by 10.7% in the second quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 145 shares in the last quarter. Envestnet Asset Management Inc. increased its position in GW Pharmaceuticals PLC by 23.7% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,376 shares of the biopharmaceutical company’s stock worth $154,000 after buying an additional 264 shares in the last quarter. BNP Paribas Arbitrage SA bought a new position in GW Pharmaceuticals PLC during the second quarter worth $163,000. Finally, Woodmont Investment Counsel LLC bought a new position in GW Pharmaceuticals PLC during the second quarter worth $201,000. 74.98% of the stock is currently owned by institutional investors.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

What are top analysts saying about GW Pharmaceuticals PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GW Pharmaceuticals PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit